Clifford Chance
Clifford Chance advises Fosun Kairos on License Agreement with Kite Pharma
9 January 2025
Clifford Chance advises Fosun Kairos on License Agreement with Kite Pharma
Global law firm Clifford Chance has advised Fosun Kairos Biotechnology Co., Ltd. (Fosun Kairos) on its license agreement with Kite Pharma Inc (Kite Pharma).
Fosun Kairos is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical Group (Fosun Pharma). It was previously a joint venture between Fosun Pharma and Kite Pharma, and known as Fosun Kite Biotechnology.
Following Fosun Pharma's recently completed acquisition of Kite Pharma's equity interest in the joint venture, Fosun Kairos completed a thorough amendment and restatement of its license agreement with Kite Pharma.
Shanghai partner Yang Yi said, "We are honoured to have supported Fosun Kairos in this strategic transaction. It continues to demonstrate our ability to deliver comprehensive legal solutions to clients in the life sciences industry."
Yi was supported by New York counsel Daryl Fairbairn and other Clifford Chance colleagues in China.
高伟绅就复星凯瑞与Kite Pharma的许可协议更新提供国际法律服务
国际领先律师事务所高伟绅近期就复星凯瑞（上海）生物科技有限公司（复星凯瑞）与Kite Pharma Inc (Kite Pharma)的许可协议更新，为复星凯瑞提供国际法律服务。
复星凯瑞前称为复星凯特生物技术有限公司，原为复星医药与Kite Pharma的合营企业。复星医药最近完成对Kite Pharma在该合营企业中的股权收购。该合营企业现为复星医药的全资子公司，且名称变更为复星凯瑞。复星凯瑞也与Kite Pharma就原许可协议进行了全面修订及重述。
高伟绅上海办公室合伙人杨毅、纽约办公室资深顾问律师Daryl Fairbairn以及高伟绅中国团队律师就复星凯瑞修订并重述其与Kite Pharma的许可协议提供国际法律服务。
杨毅律师表示：" 我们很荣幸能够支持复星凯瑞完成这项战略交易。该交易再次证明了高伟绅为生命科学行业客户提供全面法律解决方案的强大实力。"
